$200.85 Million in Sales Expected for Medpace Holdings Inc (NASDAQ:MEDP) This Quarter

Wall Street analysts predict that Medpace Holdings Inc (NASDAQ:MEDP) will announce $200.85 million in sales for the current quarter, Zacks reports. Five analysts have made estimates for Medpace’s earnings. The highest sales estimate is $205.10 million and the lowest is $192.14 million. Medpace reported sales of $170.14 million in the same quarter last year, which indicates a positive year over year growth rate of 18%. The business is scheduled to issue its next quarterly earnings report on Monday, July 29th.

According to Zacks, analysts expect that Medpace will report full year sales of $827.33 million for the current financial year, with estimates ranging from $825.10 million to $829.90 million. For the next year, analysts expect that the business will report sales of $932.01 million, with estimates ranging from $915.61 million to $947.40 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Medpace.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, April 29th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.60 by $0.04. Medpace had a return on equity of 17.16% and a net margin of 10.49%. The company had revenue of $200.70 million during the quarter, compared to analysts’ expectations of $190.16 million. During the same period last year, the business posted $0.60 earnings per share. The firm’s revenue was up 23.1% compared to the same quarter last year.

A number of equities research analysts have commented on MEDP shares. ValuEngine cut Medpace from a “buy” rating to a “hold” rating in a research note on Tuesday, April 16th. Wolfe Research began coverage on Medpace in a research note on Tuesday, April 2nd. They issued an “outperform” rating for the company. TheStreet upgraded Medpace from a “c” rating to a “b-” rating in a research note on Thursday, June 6th. BidaskClub upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Wednesday, March 20th. Finally, Zacks Investment Research upgraded Medpace from a “sell” rating to a “hold” rating and set a $63.00 price objective for the company in a research note on Wednesday, May 1st. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $59.25.

Medpace stock opened at $62.10 on Wednesday. The company has a 50-day simple moving average of $56.70. The company has a debt-to-equity ratio of 0.09, a quick ratio of 0.69 and a current ratio of 0.69. Medpace has a one year low of $41.84 and a one year high of $71.66. The stock has a market capitalization of $2.19 billion, a PE ratio of 23.98, a PEG ratio of 1.89 and a beta of 1.42.

In other news, CFO Jesse J. Geiger sold 25,037 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $60.00, for a total value of $1,502,220.00. Following the completion of the transaction, the chief financial officer now directly owns 25,037 shares in the company, valued at $1,502,220. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Jesse J. Geiger sold 12,000 shares of the firm’s stock in a transaction dated Friday, March 29th. The stock was sold at an average price of $58.20, for a total value of $698,400.00. Following the completion of the transaction, the chief financial officer now owns 25,037 shares of the company’s stock, valued at $1,457,153.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 44,983 shares of company stock valued at $2,661,091. Company insiders own 24.20% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Rhumbline Advisers grew its holdings in shares of Medpace by 253.7% during the 4th quarter. Rhumbline Advisers now owns 67,419 shares of the company’s stock valued at $3,568,000 after purchasing an additional 48,360 shares during the last quarter. SG Americas Securities LLC grew its holdings in shares of Medpace by 98.8% during the 4th quarter. SG Americas Securities LLC now owns 4,041 shares of the company’s stock valued at $214,000 after purchasing an additional 2,008 shares during the last quarter. State Board of Administration of Florida Retirement System grew its holdings in shares of Medpace by 60.6% during the 4th quarter. State Board of Administration of Florida Retirement System now owns 6,508 shares of the company’s stock valued at $344,000 after purchasing an additional 2,455 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of Medpace by 4.0% during the 4th quarter. Victory Capital Management Inc. now owns 4,500 shares of the company’s stock valued at $238,000 after purchasing an additional 173 shares during the last quarter. Finally, Jennison Associates LLC grew its holdings in shares of Medpace by 1.9% during the 4th quarter. Jennison Associates LLC now owns 13,942 shares of the company’s stock valued at $738,000 after purchasing an additional 260 shares during the last quarter. Institutional investors own 76.70% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Further Reading: Why does the United States have a lingering trade deficit?

Get a free copy of the Zacks research report on Medpace (MEDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.